Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 4 Review of the response to platinum retreatment in patients who were tested with tNGS (11 cases) and OncoScan® FFPE platform (15 cases)

From: Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes

ID Pre-treatment CA125 Post-treatment
CA125
CA125 Confirmation Largest lesion pre -treatment Largest lesion post-treatment Treatment Response
1 102.9 32.2 SUV 4.54 in pelvis No PET-CT contrast enhancement CR
2 115 62 31 Pleural (72 mm) Pleural (70 mm) PR
3 40.9 20.1 17.1 Peritoneal (31 mm) Peritonium (26 mm) SD
4 637 1143 Liver (45 mm) Liver (54 mm) DP
5 92.3 79 24.2 Peritoneal (63 mm) Peritonium
(47 mm)
PR
6 35 18.6 0 SUV 11.0 in liver, 3.2 in adrenal, 8.0 pre-sacral No PET-CT contrast enhancement CR
7 1174 222,9 71.5 Pleural effusion Pleural effusion resolution* PR
8 258 331 SUV 3.0 in peritoneal lesion, 1.9 in epiplon, 3.0 in gut SUV 11.6 in peritoneal lesion, 3.7 in epiplon, 9.5 in gut DP
9 Bowel obstruction DP
10 4430 1887 2180 Pelvic (101 mm) Pelvic (90 mm) PR
11 546 81.6 60 Pre-sacral (117 mm) Pre-sacral
(106 mm)
PR
12 2600 3004 Peritoneal thickening New hepatic lesion (24 mm) DP
13 32 14.2 17.6 Retroperitoneal lesion (40 mm) Retroperitoneal lesion (40 mm) SD
14 Bowel obstruction DP
15 52.2 94.6 185 New brain lesion DP
  1. CA125 confirmation: a second CA125 measurement at least two weeks after the post treatment was performed aiming to confirm the treatment response; PET-CT FDG positron emission tomography – compute tomography, SUV standardized uptake value, CR complete response, PR partial response, SD stable disease, DP disease progression
  2. *No surgical procedure was performed between the evaluations